Zevra Therapeutics

ZVRA

Market cap $766M

Data published in Molecular Genetics and Metabolism Reports suggest MIPLYFFA (arimoclomol) was well tolerated in pediatric patients with no new safety signals observed Data published in Molecular Genetics and Metabolism Reports suggest MIPLYFFA (arimoclomol) was well tolerated in pediatric patients with no new safety signals observed

BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, announced today that its Chief Medical Officer (“CMO”) Adrian Quartel, M.D., FFPM, will be stepping down from his position due to personal reasons, effective July 3, 2026. Dr. Quartel will continue to support Zevra in a consulting capacity through December 31, 2026, while the Company conducts a search for its next CMO and ensures a seamless transition.

Zevra Therapeutics (NASDAQ:ZVRA) said it has submitted a patent covering its product MIPLYFFA for listing in the US Food and Drug Administration's Orange Book, with patent protection extending to 2041. The submission seeks to list the patent in the Orange Book, the FDA's register of approved drug products and the patents associated with them, the company said.

MIPLYFFA patent submitted for Orange Book listing, with patent protection to 2041 Separately filed patent term extension remains pending with the U.S. Patent and Trademark Office BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that it has submitted U.S. Patent No. 11,707,456 for MIPLYFFA® (arimoclomol) to the U.S. Food and Drug Administration for listing in the publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book.

BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that the Company has granted options to purchase an aggregate of 33,000 shares of the Company's common stock (the “Inducement Awards”) to four new employees pursuant to the Company's 2023 Employment Inducement Award Plan. Each Inducement Award vests over four years, with 25% vesting on the first anniversary of the employee's start date, and the remainder vesting in three equal annual installments thereafter (subject to each such employee's continued employment on each vesting date).

BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra's executive leadership team will present at the H.C. Wainwright BioConnect Investor Conference in New York, NY on Tuesday, May 19, 2026, at 9:00 a.m. ET.

Zevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call Transcript

Zevra Therapeutics (ZVRA) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $0.06 per share a year ago.

Q1 2026 net revenue of $36.2 million , a 78% increase over Q1 2025 Completed $50.0 million sale of SDX portfolio to Commave Therapeutics Operational execution fueled strong cash position of $236.8 million Company to host conference call and webcast TODAY, May 6, 2026 , at 4:30 p.m. ET BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the first quarter ended March 31, 2026.

BOSTON, March 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted as of March 18, 2026 an equity inducement award to Justin Renz, the Company's new Chief Financial Officer pursuant to the Company's 2023 Employment Inducement Award Plan (as amended and/or restated, the “Inducement Award Plan”). The equity award was approved by the Compensation Committee of the Board of Directors in accordance with Nasdaq Rule 5635(c)(4) and made as a material inducement to Mr. Renz upon acceptance of employment with Zevra.